Get started
Author

Carys Morgan

Observed names: C Morgan, C. Morgan, Carys A. Morgan
Observed institutions: Velindre NHS Trust, At Bristol, University of Bristol, National Health Service Wales, Velindre Cancer Centre, AstraZeneca (United States)
ORCID: 0000-0001-7000-2210
Observed ORCID: 0000-0001-7000-2210
OpenAlex ID: A5074566433
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
2023 · John V Reynolds, Shaun R Preston, et al. · The Lancet. Gastroenterology & hepatology · 211
PDF
Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer
2011 · E E Vincent, D J E Elder, et al. · British Journal of Cancer · 205
PDF
Study to Determine Adequate Margins in Radiotherapy Planning for Esophageal Carcinoma by Detailing Patterns of Recurrence After Definitive Chemoradiotherapy
2008 · Michael R. Button, Carys A. Morgan, et al. · International Journal of Radiation Oncology*Biology*Physics · 84
Management of uncommon chemotherapy-induced emergencies
2011 · Carys Morgan, Tania Tillett, et al. · The Lancet Oncology · 49
Glycogen Synthase Kinase 3 Protein Kinase Activity Is Frequently Elevated in Human Non-Small Cell Lung Carcinoma and Supports Tumour Cell Proliferation
2014 · Emma E. Vincent, Douglas J. E. Elder, et al. · PLoS ONE · 30
PDF
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma
2023 · Mairéad G. McNamara, Jayne Swain, et al. · EClinicalMedicine · 28
PDF
Impact of Positron Emission Tomography and Endoscopic Ultrasound Length of Disease Difference on Treatment Planning in Patients with Oesophageal Cancer
2017 · K.G. Foley, C. Morgan, et al. · Clinical Oncology · 17
NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).
2022 · Mairead Geraldine McNamara, Jayne Swain, et al. · Journal of Clinical Oncology · 13
397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305
2024 · M. Moehler, D-Y. Oh, et al. · Annals of Oncology · 12
PDF
Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study
2024 · C. Fong, B. Patel, et al. · ESMO Open · 9
PDF
Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.
2021 · Caroline Fong, Bijal Patel, et al. · Journal of Clinical Oncology · 9
Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study.
2020 · David Cunningham, Caroline Yean Kit Fong, et al. · Journal of Clinical Oncology · 5
Management of gastrointestinal stromal tumours
2015 · Carys Morgan, Kate Parker, et al. · Cambridge University Press eBooks · 5
Rationale and design of a UK database for a rare cancer type: the GEM Registry for gastrointestinal stromal tumours
2013 · V R Bulusu, J Fullarton, et al. · British Journal of Cancer · 5
PDF
Ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Secondary analysis of efficacy and safety results of 4 dosing regimens in the phase II trial I4T-MC-JVDB.
2018 · Jaffer A. Ajani, Anghel Adrian Udrea, et al. · Journal of Clinical Oncology · 3
A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB
2017 · J.A. Ajani, A. Udrea, et al. · Annals of Oncology · 3
PDF
123P Updated safety of perioperative durvalumab for resectable NSCLC in AEGEAN
2024 · L. Urban, T. Winder, et al. · ESMO Open · 2
Gastric Radiotherapy in the UK – Current Practice and Opinion on Future Directions
2023 · A.N. Case, H. Hutchings, et al. · International Journal of Radiation Oncology*Biology*Physics · 2
NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).
2023 · Mairead Geraldine McNamara, Jayne Swain, et al. · Journal of Clinical Oncology · 2
PDF
1424P Maintenance capecitabine plus ramucirumab after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma (OGA): Final analysis from the PLATFORM trial
2024 · A. Gordon, Z. Rajan, et al. · Annals of Oncology · 1
PDF
The clinical utility of plasma cell-free DNA (cfDNA) in NET-02: Randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).
2024 · Mairead Geraldine McNamara, Simon Pearce, et al. · Journal of Clinical Oncology · 1
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
2022 · Manish A. Shah, Anghel Adrian Udrea, et al. · Cancers · 1
PDF
Flip-flop Oesophageal Movement During Radical Radiotherapy for Oesophageal Malignancy
2020 · P. Shaw, L. Wills, et al. · Clinical Oncology · 1
Audit of Patients Receiving Palliative Chemotherapy for Oesophago-gastric Cancer at Velindre Cancer Centre in 2012
2014 · C. Powell, R. Trickey, et al. · Clinical Oncology · 1
PDF
Haematological toxicity after peptide receptor radionuclide therapy in neuroendocrine tumours - a 10 year experience from south wales
2025 · Rajeev Sasikumar, Archana Krishnakumar, et al. · Endocrine Abstracts
Works count: 39
Citation count: 699
H-index: 9
I10-index: 9
Year
Topic
Type